Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals

PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals

(2023) Amitis Ramezani et al.   Scientific Reports

Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine

(2023) Ehsan Mostafavi et al.   JAMA Network Open

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine

(2023) Behrokh Farahmand et al.   Heliyon

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

(2022) Wanwisa Dejnirattisai et al.   CELL

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

(2022) Victoria Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review

(2022) Santenna Chenchula et al.   JOURNAL OF MEDICAL VIROLOGY

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study

(2022) Cristina Menni et al.   LANCET INFECTIOUS DISEASES

Covid-19: Mix and match booster vaccination approach offers best protection, study reports

(2022) Elisabeth Mahase   BMJ-British Medical Journal

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

(2022) Pengfei Jin et al.   PLOS MEDICINE

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents

(2022) David H. Canaday et al.   EBioMedicine

Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran

(2022) Mona Sadat Larijani et al.   MICROBIAL PATHOGENESIS

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

(2022) María Eugenia-Toledo-Romaní et al.   VACCINE

Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates

(2021) Qian He et al.   Emerging Microbes & Infections

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2021) Shilong Yang et al.   LANCET INFECTIOUS DISEASES

Prolonged Viral Shedding and Antibody Persistence in Patients with COVID-19

(2021) Fatemeh Fotouhi et al.   MICROBES AND INFECTION

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disease-drug and drug-drug interaction in COVID-19: Risk and assessment

(2021) Devendra Kumar et al.   BIOMEDICINE & PHARMACOTHERAPY

Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?

(2021) Ali Hamady et al.   INFECTION

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

(2021) Matthias Tenbusch et al.   LANCET INFECTIOUS DISEASES

Evaluation of transduced dendritic cells expressing HIV-1 p24-Nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine

(2021) Mona Sadat Larijani et al.   VIRUS RESEARCH

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

(2021) Arabella S V Stuart et al.   LANCET

SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up

(2021) Mostafa Salehi-Vaziri et al.   MICROBIAL PATHOGENESIS

Science-based COVID-19 vaccine development

(2021) George F Gao   National Science Review

Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples

(2020) Alessandro Manenti et al.   JOURNAL OF MEDICAL VIROLOGY

Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles

(2020) Mona Sadat Larijani et al.   Current Drug Delivery

Approaches and Challenges in SARS-CoV-2 Vaccine Development

(2020) Gabriel Dagotto et al.   Cell Host & Microbe

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007–2018: A retrospective cohort study

(2020) Meijuan Li et al.   Journal of Infection and Public Health